Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADCT-301 in Relapsed/Refractory CD25-positive AML or ALL
NCT02588092Phase 1Terminated
- Sponsor
- ADC Therapeutics
- Start
- Feb 2016
- Primary completion
- Aug 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of camidanlumab tesirine in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) (2 arms), sponsored by ADC Therapeutics. Primary endpoints: Dose-Limiting Toxicities, Recommended Dose of ADCT-301 and 2 more. Started Feb 2016; status: terminated.
02
Drugs
camidanlumab tesirine
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02588092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02588092.